SurModics (SRDX) Tops Q4 EPS by 8c, Revenues Beat; FY19 EPS Mid-Point Below Consensus, FY18 Revenue Outlook Above Consensus

November 9, 2018 7:32 AM EST

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

SurModics (NASDAQ: SRDX) reported Q4 EPS of $0.05, $0.08 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $23 million versus the consensus estimate of $21.56 million.

  • Revenue of $23.0 million, an increase of 15% year-over-year
  • GAAP EPS of ($0.13), non-GAAP EPS of $0.05
  • Submitted application for first in-human study for arteriovenous (AV) access drug coated balloon (DCB)
  • Fiscal 2019 revenue outlook of $92.0 to $97.0 million, GAAP EPS outlook of ($0.32) to ($0.02)

“We continue to drive strong revenue growth and solid operational performance as we execute on our strategic objectives,” said Gary Maharaj, President & CEO of Surmodics. “The positive twelve-month data recently presented from PREVEIL, the early feasibility study of our SurVeil® DCB and the recent submission for first in-human study for our AV access DCB, AVess™, demonstrate meaningful progress towards our whole-products solutions initiatives.”


SurModics sees FY2019 EPS of ($0.07)-$0.23, versus the consensus of $0.23. SurModics sees FY2019 revenue of $92-97 million, versus the consensus of $90.37 million.

For earnings history and earnings-related data on SurModics (SRDX) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Earnings, Guidance, Hot Guidance, Management Comments

Related Entities